SUPPORT LINE

0300 111 1234

Message

EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

View e-Privacy Directive Documents

You have declined cookies. This decision can be reversed.

Tolvaptan

Read here the history of Tolvaptan.

To access the latest papers published on Tolvaptan, please visit PubMed website. (The search terms used to show this page of results were 'tolvaptan' AND 'polycystic kidney disease'.)

JINARC® (tolvaptan) approved in Europe

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive

On 28 May, 2015, the first-ever drug therapy for adults with ADPKD, was approved in Europe.

JINARC® - the brand name of the drug we know more commonly as tolvaptan - was developed by Otsuka Pharmaceutical Co Ltd. The company was granted marketing authorisation for JINARC® (tolvaptan) based on the findings of the pivotal Phase III randomised, double-blind and placebo-controlled TEMPO 3:4 trial – the largest clinical study conducted in ADPKD to date.

Click here for more information about Tolvaptan.

PrintEmail

NICE will appraise Tolvaptan

User Rating: 3 / 5

Star ActiveStar ActiveStar ActiveStar InactiveStar Inactive

The Department of Health has asked NICE - the National Institute for Health and Care Excellence - to conduct an appraisal of tolvaptan for treating ADPKD (autosomal dominant polycystic kidney disease). The date of the appraisal meeting will be 1st April 2015.

Continue Reading

PrintEmail

Tolvaptan Trial Results Announced

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive

At the American Society of Nephrology (ASN) meeting on 3 November 2012, Dr Vicente Torrres from the Mayo Clinic, together with research collaborators, reported the results of a 3 year global study known as TEMPO - Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease Outcomes.

Continue Reading

PrintEmail

Latest Tweets

PKD Charity is a Member of

  • Visit Ciliopathy Alliance website
  • Visit PKD International website
  • Visit EURORDIS website
  • Visit the Genetic Alliance UK website
  • Visit The Information Standard website
  • National Voices Website
  • Rare Disease UK Website
  • Specialised Healthcare Alliance Website
  • FEDERG Website